Potential Role of Nrf2, HER2, and ALDH in Cancer Stem Cells: A Narrative Review
- PMID: 38356054
- DOI: 10.1007/s00232-024-00307-2
Potential Role of Nrf2, HER2, and ALDH in Cancer Stem Cells: A Narrative Review
Abstract
Cancer is one of the main causes of death among humans, second only to cardiovascular diseases. In recent years, numerous studies have been conducted on the pathophysiology of cancer, and it has been established that this disease is developed by a group of stem cells known as cancer stem cells (CSCs). Thus, cancer is considered a stem cell disease; however, there is no comprehensive consensus about the characteristics of these cells. Several different signaling pathways including Notch, Hedgehog, transforming growth factor-β (TGF-β), and WNT/β-catenin pathways cause the self-renewal of CSCs. CSCs change their metabolic pathways in order to access easy energy. Therefore, one of the key objectives of researchers in cancer treatment is to destroy CSCs. Nuclear factor erythroid 2-related factor 2 (Nrf2) plays an essential role in the protection of CSCs from reactive oxygen species (ROS) and chemotherapeutic agents by regulating antioxidants and detoxification enzymes. Human epidermal growth factor receptor 2 (HER2) is a member of the tyrosine kinase receptor family, which contributes to the protection of cancer cells against treatment and implicated in the invasion, epithelial-mesenchymal transition (EMT), and tumorigenesis. Aldehyde dehydrogenases (ALDHs) are highly active in CSCs and protect the cells against damage caused by active aldehydes through the regulation of aldehyde metabolism. On the other hand, ALDHs promote the formation and maintenance of tumor cells and lead to drug resistance in tumors through the activation of various signaling pathways, such as the ALDH1A1/HIF-1α/VEGF axis and Wnt/β-catenin, as well as changing the intracellular pH value. Given the growing body of information in this field, in the present narrative review, we attempted to shed light on the function of Nrf2, HER2, and ALDH in CSCs.
Keywords: Aldehyde dehydrogenases; Cancer stem cells; Chemotherapy; HER2; Nuclear factor erythroid 2-related factor 2.
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Similar articles
-
High NRF2 level mediates cancer stem cell-like properties of aldehyde dehydrogenase (ALDH)-high ovarian cancer cells: inhibitory role of all-trans retinoic acid in ALDH/NRF2 signaling.Cell Death Dis. 2018 Aug 30;9(9):896. doi: 10.1038/s41419-018-0903-4. Cell Death Dis. 2018. PMID: 30166520 Free PMC article.
-
Role of Nrf2 and mitochondria in cancer stem cells; in carcinogenesis, tumor progression, and chemoresistance.Biochimie. 2020 Dec;179:32-45. doi: 10.1016/j.biochi.2020.09.014. Epub 2020 Sep 15. Biochimie. 2020. PMID: 32946993 Review.
-
Aldehyde dehydrogenases and cancer stem cells.Cancer Lett. 2015 Dec 1;369(1):50-7. doi: 10.1016/j.canlet.2015.08.018. Epub 2015 Aug 28. Cancer Lett. 2015. PMID: 26319899 Review.
-
Nuclear Factor Erythroid-Derived 2-Like 2-Induced Reductive Stress Favors Self-Renewal of Breast Cancer Stem-Like Cells via the FoxO3a-Bmi-1 Axis.Antioxid Redox Signal. 2020 Jun;32(18):1313-1329. doi: 10.1089/ars.2019.7730. Epub 2020 Jan 8. Antioxid Redox Signal. 2020. PMID: 31672029
-
Exploring the Role and Pathophysiological Significance of Aldehyde Dehydrogenase 1B1 (ALDH1B1) in Human Lung Adenocarcinoma.Int J Mol Sci. 2024 Sep 25;25(19):10301. doi: 10.3390/ijms251910301. Int J Mol Sci. 2024. PMID: 39408636 Free PMC article.
Cited by
-
Contribution of tumor microenvironment (TME) to tumor apoptosis, angiogenesis, metastasis, and drug resistance.Med Oncol. 2025 Mar 14;42(4):108. doi: 10.1007/s12032-025-02675-8. Med Oncol. 2025. PMID: 40087196 Review.
-
The cross-talk between NRF2 and apoptosis in cancer.Med Mol Morphol. 2025 Sep;58(3):155-162. doi: 10.1007/s00795-025-00434-2. Epub 2025 Mar 24. Med Mol Morphol. 2025. PMID: 40126632 Review.
References
-
- Abgarmi ZM, Lotfi AS, Abroun S, Soleimani M, Ganji SM (2018) Inhibition of Erbb2 by trastuzumab induces oxidative stress markers in HER2 positive breast cancer cell lines. J Res Med Dental Sci 6(3):158–165
-
- Ayob AZ, Ramasamy TS (2018) Cancer stem cells as key drivers of tumour progression. J Biomed Sci 25(1):20. https://doi.org/10.1186/s12929-018-0426-4 - DOI - PubMed - PMC
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous